Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | TNKS | O95271 | 15/20 | 0.57 |
| ▸ | TNKS2 | Q9H2K2 | 15/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.51 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.51 |
| ▸ | PARP1 | P09874 | 1/20 | 0.51 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.51 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.51 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12342910 | 0.81 | HPGD (1.00) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL15188523 | 0.80 | HPGD (0.66) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL1035103 | 0.79 | HPGD (0.77) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL1081986 | 0.77 | HPGD (0.75) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL1031367 | 0.77 | ALDH1A1 (1.00) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL21989243 | 0.75 | HPGD (0.59) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL15173439 | 0.74 | HPGD (0.69) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL22057404 | 0.73 | POLB (0.59) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL15173047 | 0.73 | HPGD (0.68) | HPGDALDH1A1TSHRPOLBTNKS | |
| SCHEMBL15173100 | 0.73 | TNKS (0.72) | HPGDALDH1A1TSHRPOLBTNKS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | RIKEN (JP) | 2022-08-16 | — | — | US | disclosed |
| CN-110023315-B | Novel compound or pharmacologically acceptable salt thereof | 国立研究开发法人理化学研究所 | 2021-11-12 | — | — | CN | disclosed |
| EP-3480198-B1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2021-05-05 | — | — | EP | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2020-06-04 | — | — | US | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
| EP-3480198-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | RIKEN (JP) | 2019-05-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11414429-B2 | Compound or pharmaceutically acceptable salt thereof | DPP8, DPP7, AZI2 | HPGD 3082/4885ALDH1A1 115/4885TSHR 2356/4885 |
| US-20200172554-A1 | NOVEL COMPOUND OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | DPP8, DPP7, AZI2 | HPGD 3129/4885ALDH1A1 170/4885TSHR 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.